ASCO: ctDNA Analysis Guides Treatment of Stage II Colon Cancer
MONDAY, June 6, 2022 -- A circulating tumor DNA (ctDNA)-guided approach to treatment of stage II colon cancer reduces adjuvant chemotherapy use without affecting recurrence-free survival, according to a study published online June 4 in the New...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Colon Cancer | Colorectal Cancer | Pharmaceuticals | Study